OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT
PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Addendum Agreement to License and Cooperation Agreement for Perifosine
by and between
Zentaris GmbH, Weismüllerstrasse 45, D-60314 Frankfurt am Main
- herein " Zentaris "
AOI Pharma, Inc., 750 Lexington Avenue, 26 th Floor, New York, New York 10022, USA
- herein " AOI " -
Zentaris and AOI herein each a " Party "
and collectively " Parties "
regarding pharmaceutical activities for Perifosine to be provided by Zentaris.
WHEREAS, AOI and Zentaris have entered into a License Agreement for Perifosine dated September
18, 2002 regarding the development, manufacturing and commercialization of Perifosine ("License Agreement").
This addendum is made to define the agreement of the Parties with respect to the Pharmaceutical Development of
Perifosine API and Perifosine Drug Product.
The terms employed in this addendum shall have the same meaning as specified in Section 1 of the
License Agreement. Additional terms are defined as follows:
*Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission
"CMC Representatives" shall mean the personnel designated by each party (refer to § 4) to
make decision on tasks and timing required for Pharmaceutical Development of Perifosine.
"Development Services" shall mean and include certain activities to execute the plan for
Pharmaceutical Development as herein appended or as subsequently modified by the Parties, or
to produce Perifosine API and/or Drug Product for use in clinical trials. The Parties agree that
such Development Services shall be provided by Zentaris unless Zent